Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls

MS Hofman, RJ Hicks, T Maurer, M Eiber - Radiographics, 2018 - pubs.rsna.org
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is
overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity …

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

MJM Uijen, YHW Derks, RIJ Merkx… - European journal of …, 2021 - Springer
In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms

RAS Fragomeni, T Amir, S Sheikhbahaei… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …

Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives

P Backhaus, B Noto, N Avramovic, LS Grubert… - European journal of …, 2018 - Springer
Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

PSMA radioligand uptake as a biomarker of neoangiogenesis in solid tumours: diagnostic or theragnostic factor?

A Rizzo, S Dall'Armellina, DA Pizzuto, G Perotti… - Cancers, 2022 - mdpi.com
Simple Summary Positron emission tomography/computed tomography (PET/CT) has an
increasingly relevant role in the management of oncological patients. It consists of the …

PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical …

A Holzgreve, A Biczok, VC Ruf… - Frontiers in …, 2021 - frontiersin.org
Aim The aim of the current study was to enlighten the evolution of prostate-specific
membrane antigen (PSMA) expression in glioblastoma between initial diagnosis and …

[HTML][HTML] A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

J Bolcaen, J Kleynhans, S Nair, J Verhoeven… - Theranostics, 2021 - ncbi.nlm.nih.gov
Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma
(GB) remains a challenge. The current survival rate of GB averages one year, even with an …

A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer

S Brunello, N Salvarese, D Carpanese, C Gobbi… - Molecules, 2022 - mdpi.com
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of …

68Ga–Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?

J Kunikowska, R Kuliński, K Muylle… - Clinical Nuclear …, 2020 - journals.lww.com
Background Glioblastoma multiforme (GBM) is the most common and most aggressive
primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of …

Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study

A Sasikumar, R Kashyap, A Joy, KC Patro… - Clinical Nuclear …, 2018 - journals.lww.com
Background Imaging of gliomas remains challenging. The aim of the study was to assess the
feasibility of using 68 Ga-PSMA-11 PET/CT for imaging gliomas. Methods Fifteen patients …